Meijisubsidiary Meiji Seika Pharma has commenced a Phase III clinical trial of a messenger ribonucleic acid (mRNA) vaccine, ARCT-154, for Covid-19 in Japan.
The observer-blind, multicentre, randomised, active-controlled, comparative trial is funded partially by the Ministry of Health, Labour and Welfare of Japan.
It will analyse the immunogenicity and safety of ARCT-154 in healthy adult subjects aged 18 years and above.
The trial will enrol subjects who have previously received three doses of an approved mRNA Covid-19 vaccine, a minimum of three months ago.
It anticipates enrolling a total of 780 subjects, with 390 each in the ARCT-154 and Comirnaty arms.
In the trial, a 5µg intramuscular dose of ARCT-154 will be given to trial subjects.
The trial, which started in November this year, will continue until April 2024.
Developed by Arcturus Therapeutics, ARCT-154 is claimed to be effective against SARS-CoV-2 viral variants, including the Omicron variant.
In addition, the vaccine could require a low vaccination dosage and have long-lasting effects.
Meiji also has plans to set up a domestic production system, using a subsidy from the Ministry of Economy, Trade and Industry.
In April this year, the company dosed the first subject in a Phase II clinical trial of a selective phosphodiesterase-4 (PDE4) inhibitor, ME3183, in plaque psoriasis patients in the US and Canada.
The double-blind, randomised, placebo-controlled trial was designed to assess the safety, efficacy, and tolerability of ME3183 for 16 weeks.
A total of 125 subjects were planned to be enrolled at nearly 30 US and Canadian sites for this trial.
Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.